The Medical Letter on Drugs and Therapeutics
Two New Drugs for Chronic ITP
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Romiplostim (Nplate – Amgen), a recombinant fusion protein injected subcutaneously, and eltrombopag (Promacta – GlaxoSmithKline), a non-peptide taken orally, have been approved by the FDA for treatment of chronic immune thrombocytopenic purpura (ITP) refractory to corticosteroids, immunoglobulins and/or splenectomy.

MECHANISM OF ACTION — ITP has traditionally been attributed to antibody-mediated peripheral platelet destruction, but impaired platelet production is now known to play a role as well. Thrombopoietin values are normal or low in most patients with ITP. Romiplostim and eltrombopag have no structural resemblance to thrombopoietin, but they both bind to and activate the human thrombopoietin receptor, stimulating megakaryocyte development and platelet production. Unlike romiplostim, eltrombopag does not compete for the same binding site as endogenous ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Two New Drugs for Chronic ITP
Article code: 1305b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian